CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled / 40 target
Drug / intervention
Intervention: Dietary Supplement with Plant Extracts +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07240246
NCT07240246N/ACompletedHigh Momentum (4.8/mo)Completion was 3mo ago

Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response

FFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & Innovation·interventional·Posted Nov 20, 2025·Updated Jun 15, 2026

In Brief

A clinical study evaluating Intervention: Dietary Supplement with Plant Extracts and Placebo for GLP-1 and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

Obesity is a chronic condition linked to numerous health risks and affects more than one billion people worldwide. While pharmacological treatments such as incretin-based therapies are available, they may have side effects, are not suitable for all patients, and adherence can be limited. Dietary supplements that influence appetite and satiety may represent an alternative or complementary approach. This study will evaluate whether a dietary supplement containing plant extracts stimulates the intestinal incretin response. The primary focus is the effect on glucagon-like peptide-1 (GLP-1) secretion. Secondary outcomes include dipeptidyl peptidase-4 (DPP-4), gastric inhibitory peptide (GIP), and insulin, as well as measures of appetite, satiety, food intake, and anthropometrics. The trial is designed as a 12-week, double-blind, randomized, placebo-controlled parallel-group study in adults with overweight or obesity (BMI 25-40, age 18-50). Participants will receive either the dietary supplement or placebo. Blood samples will be collected at baseline and after 12 weeks, both fasting and following capsule intake and a standardized liquid meal. Anthropometric measurements and visual analog scales (VAS) for hunger and satiety will also be assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria

Timeline

N/ACompletedFinished
2026
First PostedNov 20, 2025
Enrollment StartOct 24, 2025
Primary CompletionMar 11, 2026
Study CompletionMay 12, 2026
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 7 months ago

Arms & Interventions

Dietary Supplementactive_comparator

Participants receive a dietary supplement: Capsule preparation containing hypromellose, calcium phosphate, inulin, yeast extract (Saccharomyces cerevisiae), bitter melon extract, green coffee bean extract, white mulberry extract, purslane extract, peppermint leaf extract, dandelion extract, green mate extract, zinc gluconate, ginger extract, biotin and yellow iron oxide (E172 - capsule colouring)

Dietary Supplement: Intervention: Dietary Supplement with Plant Extracts
Placeboplacebo_comparator

Participants receive a capsule preparation containing hypromellose, calcium phosphate, inulin and yellow iron oxide (E172 - capsule colouring agent)

Other: Placebo

Interventions

Intervention: Dietary Supplement with Plant Extractsdietary

Capsule containing a blend of plant extracts, administered twice daily three capsules (total six capsules), 30-60 minutes before main meals, for 12 weeks.

Placeboother

Matching capsule without active plant extracts, administered twice daily three capsules (in total six), 30-60 minutes before main meals, for 12 weeks.